HIGHLIGHTS
- who: Hironori Nakamura from the Department of Nephrology, Shinonoi General Hospital, u2011, Ai Shinonoi, Nagano, Japan have published the research work: Hilar lymphadenopathy, development of tubulointerstitial nephritis, and dense deposit disease following Pfizer-BioNTech COVID-19 vaccination, in the Journal: (JOURNAL) of June/29,/2021
SUMMARY
(e_g, rituximab), liposome-encapsulated products (doxil or ambisome), and micellized anticancer drug (paclitaxel). The authors present a case of a patient who developed hilar lymphadenopathy, TIN, and dense deposit disease (DDD) following mRNA_vaccination. cells. Although the enlarged lymph nodes degenerated after antibiotic treatment, they might be attributed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.